A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer.

ABSTRACT:

Introduction

Abiraterone acetate and enzalutamide are commonly employed in prostate cancer therapy in an interchangeable manner. These drugs are highly efficacious in androgen antagonism to improve patient outcomes, but they also carry noteworthy risk of adverse effects. Common toxicities vary amongst the two drugs and may have differential interactions with patient co-morbidities, but these patterns are unclear as co-morbidities typically serve as exclusion criteria in clinical trials. Hence, there is no existing guidance on how clinicians may tailor treatment based on patient-specific factors. Analysis of differential patient outcomes between these two drugs can inform future systematic reviews, new clinical studies, and clinical decision making.

Method and analysis

The fr

SUBMITTER: Shah YB 

PROVIDER: S-EPMC9423609 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature